Skip to main content
. 2019 Apr 24;3(3):e233. doi: 10.1097/HS9.0000000000000233

Figure 3.

Figure 3

BGB324 has distinct effects upon differentiation in normal and JAK2 V617F expressing cells; The effect of inhibition of AXL (3 μM BGB324) and JAK2 (50 nM Ruxolitinib) on cell proliferation and differentiation of CD34+ cells enriched from control and JAK2 V617F patients were assessed using CellTrace Violet Cell Proliferation Kit (Molecular Probes) and flow cytometry. A, displays a representative experiment for control patient cells and B, data from 4 experiments (mean ± SEM). C, displays a representative experiment for JAK2 V617F positive cells and D, amalgamated data (mean ± SEM, n = 3). E, shows the number of CD34+ cells remaining following 8 days in culture expressed as a percentage of the total cell number (calculated from 3b and 3d). The t test results are shown or represented by; ns = not significant, ∗ < 0.05.